FDA Accepts Supplement for INQOVI by Taiho Oncology
The FDA has accepted a supplemental application for INQOVI (NDA212576) from Taiho Oncology.
Asset / Drug
Drug and asset intelligence for INQOVI with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.